(19)
(11) EP 3 600 440 A1

(12)

(43) Date of publication:
05.02.2020 Bulletin 2020/06

(21) Application number: 18715453.9

(22) Date of filing: 19.03.2018
(51) International Patent Classification (IPC): 
A61K 47/60(2017.01)
A61P 1/00(2006.01)
A61P 27/02(2006.01)
 A61P 11/00(2006.01)
A61P 17/00(2006.01)
(86) International application number:
PCT/US2018/023174
(87) International publication number:
WO 2018/175340 (27.09.2018 Gazette 2018/39)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 20.03.2017 US 201762473972 P
20.03.2017 US 201762473975 P
20.03.2017 US 201762473982 P
04.05.2017 US 201762501567 P
04.05.2017 US 201762501568 P
04.05.2017 US 201762501651 P
10.05.2017 US 201762504111 P
22.11.2017 US 201762590111 P
22.11.2017 US 201762590119 P
22.11.2017 US 201762590131 P
22.11.2017 US 201762590148 P
23.02.2018 US 201862634691 P

(71) Applicant: Sienna Biopharmaceuticals, Inc.
Westlake Village, CA 91362 (US)

(72) Inventors:
  • TRAVERSA, Silvio
    Westlake Village, California 91362 (US)
  • BAGNOD, Raffaella
    Westlake Village, California 91362 (US)
  • MAINERO, Valentina
    Westlake Village, California 91362 (US)
  • HARRIS, Todd James
    Westlake Village, California 91362 (US)
  • RAVA ROSSA, Luisa, Bertarione
    Westlake Village, California 91362 (US)

(74) Representative: K&L Gates LLP 
Markgrafenstrasse 42
10117 Berlin
10117 Berlin (DE)

   


(54) REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS